Trials / Terminated
TerminatedNCT02007720
Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF
A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 876 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Serelaxin | Intravenous infusion |
| DRUG | Placebo | Intravenous infusion |
| OTHER | Standard of CareTherapy | This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc. |
Timeline
- Start date
- 2014-03-12
- Primary completion
- 2017-03-27
- Completion
- 2017-06-16
- First posted
- 2013-12-11
- Last updated
- 2019-08-02
- Results posted
- 2019-08-02
Locations
132 sites across 11 countries: China, India, Japan, Jordan, Lebanon, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand
Source: ClinicalTrials.gov record NCT02007720. Inclusion in this directory is not an endorsement.